Alternative Medications to Eplerenone
Spironolactone is the primary alternative to eplerenone and is actually considered the drug of choice for most conditions requiring mineralocorticoid receptor antagonism, including primary aldosteronism and resistant hypertension. 1, 2
Primary Alternative: Spironolactone
Spironolactone is a non-selective mineralocorticoid receptor antagonist (MRA) that is highly effective but requires 2-3 times lower doses than eplerenone to achieve equivalent blood pressure control 2. The typical dosing is:
- Starting dose: 25-50 mg daily
- Maximum dose: 400 mg daily
- Usual effective range: 50-100 mg daily for most patients 1
Key Advantages of Spironolactone:
- More potent per milligram than eplerenone
- Lower cost and wider availability
- Extensive evidence base for efficacy 3
- Demonstrated mortality benefits in heart failure 4
Important Limitations:
The major drawback is anti-androgenic side effects due to its non-selective receptor binding 2:
- Gynecomastia occurs in 10% at 25 mg/day, up to 52% at doses ≥150 mg/day 2
- Breast tenderness and mastodynia
- Sexual dysfunction and decreased libido (especially in men)
- Menstrual irregularities in women
Clinical Pearl: Gynecomastia typically appears after 1-2 months but more commonly after ≥6 months. In younger males, reducing the dose to ≤50 mg daily may resolve symptoms 1.
Secondary Alternatives: Epithelial Sodium Channel Blockers
When MRAs are not tolerated, amiloride is the recommended alternative 1, 2:
Amiloride
- Dosing: 2.5-10 mg twice daily (maximum 10 mg twice daily)
- Mechanism: Blocks epithelial sodium channels in the distal tubule
- Efficacy: Less potent than MRAs for blood pressure control 2
- Side effects: Hyperkalemia, gastrointestinal symptoms
- Best use: For patients with MRA-related adverse effects, particularly anti-androgenic symptoms 1
Triamterene
- Dosing: 100 mg twice daily (maximum 150 mg twice daily)
- Similar mechanism to amiloride
- Side effects: Primarily gastrointestinal 2
Clinical Decision Algorithm
When to choose each alternative:
First-line for most patients: Spironolactone
- Use unless patient is a young male concerned about sexual side effects
- Most cost-effective option
Switch from eplerenone to spironolactone if:
- Cost is prohibitive
- Higher potency needed for blood pressure control
- Patient has no concerns about anti-androgenic effects
Switch from spironolactone to eplerenone if:
- Gynecomastia develops (especially if dose reduction to ≤50 mg doesn't resolve it) 1
- Sexual dysfunction occurs
- Patient is a young male at high risk for these side effects
Use amiloride or triamterene when:
- Both spironolactone and eplerenone cause intolerable side effects
- Hyperkalemia risk is very high (though all potassium-sparing agents carry this risk)
- Patient specifically cannot tolerate MRAs
Critical Monitoring Requirements
All alternatives require identical monitoring 1:
- Check electrolytes and renal function 2-3 months after each dose change
- Monitor potassium carefully—hyperkalemia is the primary safety concern with all agents
- Avoid in patients with eGFR <30 mL/min/1.73 m²
- Use caution with stage 3 CKD 2
- More frequent monitoring needed if combining with ACE inhibitors or ARBs
Evidence Quality Considerations
The 2025 Endocrine Society guideline 1 and 2024 multidisciplinary consensus 2 both establish spironolactone as the reference standard. While eplerenone was developed to avoid anti-androgenic effects, no direct head-to-head trials definitively prove superior efficacy of one over the other 3, 5. The choice between them primarily depends on tolerability rather than efficacy, with spironolactone requiring lower doses to achieve similar effects.
Important caveat: Recent evidence suggests eplerenone may offer stronger mortality benefits in heart failure, while spironolactone shows greater hospitalization reduction 4, though this distinction is less relevant for primary aldosteronism or hypertension management.